Procter & Gamble Pharmaceuticals has launched a new campaign ‘Breaking the Silence’ in the UK to improve osteoporosis treatment compliance and raise awareness of upper GI side effects of osteoporosis treatment. The campaign has been set up in response to findings that show less than a third of GPs identify factors that could lead to GI side effects and just 46% routinely assess for other medications being taken at the same time, such as anticoagulants, aspirin and corticosteroids, before starting a patient on osteoporosis therapy. Consequently, pharmacists are being urged to carry out routine checks to assess whether osteoporosis patients are or are at risk of developing GI side effects and monitor patients in case such adverse events affect treatment compliance. In addition, pharmacists are being asked to check whether patients understand the dosing instructions to ensure treatments are being taken correctly.